Sage's oral post­par­tum de­pres­sion drug ticks ef­fi­ca­cy, safe­ty box­es in key tri­al, eas­ing fears of faint­ing risk

Piv­otal da­ta on Sage Ther­a­peu­tics’ $SAGE keen­ly-watched oral post­par­tum de­pres­sion (PPD) drug showed that there was no loss of con­scious­ness as­so­ci­at­ed with the ex­per­i­men­tal treat­ment, un­like the drug de­vel­op­er’s brex­anolone — which must be ad­min­is­tered via an in­fu­sion and is cur­rent­ly un­der FDA re­view. Late-stage da­ta showed the po­ten­tial block­buster drug, SAGE-217, met the pri­ma­ry end­point, al­though a se­ri­ous ad­verse event was ob­served in both the drug and place­bo arm, the com­pa­ny said on Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER